Rational of the use of aliskiren in hypertension and beyond

Area of Science:

• Cardiovascular medicine
• Pharmacology

Background:

• Arterial hypertension is a significant global mortality risk factor.
• Effective antihypertensive drugs are crucial for reducing morbidity and mortality.
• Inhibiting the renin-angiotensin-aldosterone-system (RAAS) is a key strategy for blood pressure control.

Purpose of the Study:

• To review the effects of the direct renin inhibitor aliskiren.
• To evaluate aliskiren's impact on hypertension and target organ damage.
• To discuss potential changes in morbidity and mortality associated with aliskiren therapy.

Main Methods:

• Review of existing literature on aliskiren.
• Analysis of aliskiren's mechanism of action as a direct renin inhibitor.
• Examination of studies investigating aliskiren in monotherapy and combination therapy.

Main Results:

• Aliskiren effectively inhibits plasma renin activity, targeting the rate-limiting step of the RAAS.
• Aliskiren demonstrates potential for blood pressure reduction.
• The role of aliskiren in reducing target organ damage requires further investigation.

Conclusions:

• Aliskiren represents a novel therapeutic option for hypertension management by directly inhibiting renin.
• Comprehensive assessment of aliskiren's long-term effects on cardiovascular outcomes and target organ damage is warranted.
• Future clinical trials are essential to fully elucidate the benefits of aliskiren in reducing morbidity and mortality.